Daiichi Sankyo Company, Limited, commonly referred to as Daiichi Sankyo, is a prominent global pharmaceutical firm headquartered in Tokyo, Japan. Founded in 1899, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative healthcare solutions. Specialising in the research, development, and manufacturing of pharmaceuticals, Daiichi Sankyo is particularly renowned for its contributions to oncology, cardiovascular, and vaccine development. The company’s unique approach combines cutting-edge science with a commitment to improving patient outcomes, positioning it as a leader in the pharmaceutical industry. With a rich history marked by key milestones, Daiichi Sankyo has achieved notable success, including the development of groundbreaking therapies that have transformed treatment paradigms. Its dedication to innovation and quality has solidified its reputation as a trusted name in healthcare worldwide.
How does Daiichi Sankyo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Daiichi Sankyo's score of 36 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Daiichi Sankyo reported total carbon emissions of approximately 4,602,874,000 kg CO2e globally, with specific emissions of 63,004,000 kg CO2e from Scope 1 and 2 emissions in Japan, and 208,200 kg CO2e from Scope 1 and 2 in Brazil. The company also disclosed significant Scope 3 emissions, amounting to about 4,496,153,000 kg CO2e, primarily from purchased goods and services. Daiichi Sankyo has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions by fiscal year 2050. This target encompasses both Scope 1 and Scope 2 emissions, indicating a comprehensive approach to reducing their carbon footprint. The company is currently on track to meet its five-year goals, demonstrating a commitment to sustainability and environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 217,257,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 304,293,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Daiichi Sankyo is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.